Skin rash associated with better outcomes in lung cancer patients

December 19, 2010

The development of a skin rash after treatment with cetuximab is associated with better outcomes for patients with non-small-cell lung cancer (NSCLC). Patients who developed an acne-like rash within the first 3 weeks of treatment with chemotherapy plus cetuximab lived significantly longer, experienced better progression free survival (PFS), and had a higher response rate, according to an Article published Online First in The Lancet Oncology. These findings suggest that an early skin rash could be a means of identifying patients most likely to respond to cetuximab treatment and who would gain the greatest survival benefit.

Previous studies have reported links between the occurrence and severity of an acne-like rash and the efficacy of epidermal growth factor receptor (EGFR)-targeting drugs, including cetuximab, in patients with colorectal and pancreatic cancer.

In 2009, the First-Line Erbitux in Lung Cancer (FLEX) randomised trial reported that adding cetuximab to standard chemotherapy as a first-line treatment improved survival in patients with advanced NSCLC. Of the 548 patients in the chemotherapy plus cetuximab treated group, 70% developed an acne-like rash.

In this study, Ulrich Gatzemeier from Hospital Grosshansdorf in Germany and colleagues did a subgroup analysis of patients from the FLEX study to assess whether the development of an acne-like rash in the first 3 weeks of treatment (first-cycle rash) correlated with clinical outcome.

518 patients in the chemotherapy plus cetuximab group (290 with a first-cycle rash) and 540 in the chemotherapy alone group were alive on day 21, and were included in the analysis.

Findings showed that the presence of a rash was associated with better overall survival (15.0 months vs 8.8 months), PFS (5.4 months vs 4.3 months), and a higher response rate (44.8% vs 32.0%).

The significant overall survival benefit was noted in all NSCLC histological subgroups assessed including adenocarcinoma and squamous-cell carcinoma.

The authors say: "The results of our study suggest the existence of a mechanism linking the anticancer activity of cetuximab in patients with advanced NSCLC and the early incidence of acne-like rash...An alternative explanation is that cetuximab induces rash in an unrecognised subpopulation of patients with good prognosis."

They conclude: "Further prospectively designed clinical trials will be needed to verify this finding and assess it fully in the context of possible clinical application."

In a Comment, Francesco Perrone from the Istituto Nazionale Tumori, Naples, Italy, says: "The only way to verify the hypothesis that skin rash predicts the benefit of cetuximab is a randomised trial that compares interruption versus continuation of cetuximab in patients with skin rash after 3 weeks of treatment with cetuximab and chemotherapy."

He adds that these findings: "Must be validated prospectively before we consider the introduction of cetuximab into clinical practice for the treatment of patients with advanced NSCLC."
Dr Ulrich Gatzemeier, Hospital Grosshansdorf, Grosshansdorf, Germany.
T) +49 4102 601261 E)

Dr Francesco Perrone, Istituto Nazionale Tumori, Naples, Italy.
T) +390815903522 or +390815903571 E)

For full Article and Comment, see:



Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to